MXPA06011969A - Combinacion terapeutica para tratamiento de la enfermedad de alzheimer. - Google Patents

Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.

Info

Publication number
MXPA06011969A
MXPA06011969A MXPA06011969A MXPA06011969A MXPA06011969A MX PA06011969 A MXPA06011969 A MX PA06011969A MX PA06011969 A MXPA06011969 A MX PA06011969A MX PA06011969 A MXPA06011969 A MX PA06011969A MX PA06011969 A MXPA06011969 A MX PA06011969A
Authority
MX
Mexico
Prior art keywords
disease
active
pharmaceutically acceptable
alzheimer
visit
Prior art date
Application number
MXPA06011969A
Other languages
English (en)
Spanish (es)
Inventor
Gregg H Larson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA06011969A publication Critical patent/MXPA06011969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MXPA06011969A 2004-04-14 2005-04-04 Combinacion terapeutica para tratamiento de la enfermedad de alzheimer. MXPA06011969A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
PCT/IB2005/000923 WO2005099823A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Publications (1)

Publication Number Publication Date
MXPA06011969A true MXPA06011969A (es) 2006-12-15

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06011969A MXPA06011969A (es) 2004-04-14 2005-04-04 Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.

Country Status (14)

Country Link
EP (1) EP1737539A1 (https=)
JP (1) JP2007532624A (https=)
KR (1) KR20060133008A (https=)
CN (1) CN1960781A (https=)
AU (1) AU2005232447A1 (https=)
BR (1) BRPI0509881A (https=)
CA (1) CA2562069A1 (https=)
IL (1) IL178120A0 (https=)
MX (1) MXPA06011969A (https=)
NO (1) NO20065196L (https=)
RU (1) RU2006136361A (https=)
TW (1) TW200533341A (https=)
WO (1) WO2005099823A1 (https=)
ZA (1) ZA200608239B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US11129801B2 (en) * 2016-02-11 2021-09-28 Sigmathera Sas Igmesine for use in the treatment of neurodegenerative diseases
EP3982956B1 (en) * 2019-06-14 2024-06-12 Joshua O. Atiba Triple pharmaceutical composition for proteinaceous infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
IL164317A0 (en) * 2002-04-02 2005-12-18 Janssen Pharmaceutica Nv Statin therapy for enhancing cognitive maintenance
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1585520A1 (en) * 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
CA2516990A1 (en) * 2003-03-19 2004-09-30 Ares Trading S.A. Treatment of alzheimer's disease
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
IL178120A0 (en) 2006-12-31
EP1737539A1 (en) 2007-01-03
BRPI0509881A (pt) 2007-10-16
ZA200608239B (en) 2008-06-25
NO20065196L (no) 2007-01-03
CN1960781A (zh) 2007-05-09
AU2005232447A1 (en) 2005-10-27
TW200533341A (en) 2005-10-16
KR20060133008A (ko) 2006-12-22
JP2007532624A (ja) 2007-11-15
CA2562069A1 (en) 2005-10-27
RU2006136361A (ru) 2008-04-20
WO2005099823A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
Rogers et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study
US5192753A (en) Anti-rheumatoid arthritic drugs in the treatment of dementia
Chase et al. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease
US20150209306A1 (en) Multi-component formulation for improving neurological function
Mehta et al. Amelioration of specific working memory deficits by methylphenidate in a case of adult attention deficit/hyperactivity disorder
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
Tenenbaum et al. An experimental comparison of Pycnogenol® and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Banks et al. Memories are made of this: recent advances in understanding cognitive impairments and dementia
KR20060040676A (ko) 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
JP2014530821A (ja) ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
Kirshner Mild cognitive impairment: to treat or not to treat
US20250170203A1 (en) Methods of Treating Alzheimer's Disease
US20250017946A1 (en) Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases
KR20070084123A (ko) 양극성 장애 및 관련 증상의 치료
Herrmann Cognitive pharmacotherapy of Alzheimer's disease and other dementias
MXPA06011969A (es) Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
Jann et al. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: A randomized, double-masked, placebo-controlled trial
Botter A clinical double-blind comparison of maprotiline and amitriptvline in depression
Fernandez et al. The use of methylphenidate in HIV patients: A clinical perspective
RU2233162C2 (ru) Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4
RU2703729C2 (ru) Комбинация и набор с анксиолитическим действием
Hull A Review of Dementia Treatment
Adrianne et al. LBPS 02–46 ASSOCIATION BETWEEN PERIODONTAL DISEASE AND EARLY ONSET HYPERTENSION: ANAEROBIC BACTERIA: PORPHYROMONAS GINGIVALIS: AND: TREPONEMA DENTICOLA: COULD INDUCE PERIPHERAL VASCULAR RESISTANCE IN YOUNG INDIGENOUS ADULTS ON MADURA ISLAND
Lee et al. LBPS 02-47 CARDIOVASCULAR OUTCOMES ACCORDING TO LDL CHOLESTEROL LEVELS IN EMPA-REG OUTCOME
Singh et al. To the Editor: Huntington_s disease (HD) is an autosomal dominant